J Liver Cancer.  2023 Sep;23(2):238-240. 10.17998/jlc.2023.09.12.

Sonazoid contrast-enhanced ultrasonography for the diagnosis of hepatocellular carcinoma: strengths and shortcomings

• Lee SW
• Kang MK
• Zhang X

• KMID: 2546406
• DOI: http://doi.org/10.17998/jlc.2023.09.12

Reference

References

1. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; May. 22. doi: 10.1097/HEP.0000000000000466. [Epub ahead of print].

2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69:182–236.

3. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017; 11:317–370.

4. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. J Liver Cancer. 2023; 23:1–120.

5. Jeong WK. Diagnosis of hepatocellular carcinoma using Sonazoid: a comprehensive review. J Liver Cancer. 2023; Sep. 19. doi: 10.17998/jlc.2023.08.25. [Epub ahead of print].

6. Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, et al. Contrast-enhanced US with perfluorobutane for hepatocellular carcinoma surveillance: a multicenter diagnostic trial (SCAN). Radiology. 2019; 292:638–646.

7. Kudo M, Ueshima K, Osaki Y, Hirooka M, Imai Y, Aso K, et al. Bmode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial. Liver Cancer. 2019; 8:271–280.

8. Kang HJ, Kim JH, Joo I, Han JK. Additional value of contrastenhanced ultrasound (CEUS) on arterial phase non-hyperenhancement observations (≥2 cm) of CT/MRI for high-risk patients: focusing on the CT/MRI LI-RADS categories LR-3 and LR-4. Abdom Radiol (NY). 2020; 45:55–63.

9. Tan Z, Teoh WC, Wong KM, Wansaicheong GK, Sandrasegaran K. Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI? Clin Imaging. 2020; 62:63–68.

10. Wang F, Numata K, Ruan L. Accurate assessment of vascularity of focal hepatic lesions in arterial phase imaging. Radiology. 2020; 297:E339–E340.

11. Kim TK, Noh SY, Wilson SR, Kono Y, Piscaglia F, Jang HJ, et al. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system. Clin Mol Hepatol. 2017; 23:280–289.

12. Hu J, Bhayana D, Burak KW, Wilson SR. Resolution of indeterminate MRI with CEUS in patients at high risk for hepatocellular carcinoma. Abdom Radiol (NY). 2020; 45:123–133.

13. Kudo M. Defect reperfusion imaging with Sonazoid®: a breakthrough in hepatocellular carcinoma. Liver Cancer. 2016; 5:1–7.

14. Bansal S, Gui J, Merrill C, Wong JK, Burak KW, Wilson SR. Contrast-enhanced US in local ablative therapy and secondary surveillance for hepatocellular carcinoma. Radiographics. 2019; 39:1302–1322.

15. Lv K, Zhai H, Jiang Y, Liang P, Xu HX, Du L, et al. Prospective assessment of diagnostic efficacy and safety of SonazoidTM and SonoVue® ultrasound contrast agents in patients with focal liver lesions. Abdom Radiol (NY). 2021; 46:4647–4659.

16. Li W, Li L, Zhuang BW, Ruan SM, Hu HT, Huang Y, et al. Interreader agreement of CEUS LI-RADS among radiologists with different levels of experience. Eur Radiol. 2021; 31:6758–6767.

17. Zhou H, Zhang C, Du L, Jiang J, Zhao Q, Sun J, et al. Contrastenhanced ultrasound liver imaging reporting and data system in diagnosing hepatocellular carcinoma: diagnostic performance and interobserver agreement. Ultraschall Med. 2022; 43:64–71.

18. Park J, Lee JM, Kim TH, Yoon JH. Imaging diagnosis of hepatocellular carcinoma: future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound. Clin Mol Hepatol. 2022; 28:362–379.

19. Lee JY, Minami Y, Choi BI, Lee WJ, Chou YH, Jeong WK, et al. The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using Sonazoid. Ultrasonography. 2020; 39:191–220.

20. Dietrich CF, Nolsøe CP, Barr RG, Berzigotti A, Burns PN, Cantisani V, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver - update 2020 - WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall Med. 2020; 41:562–585.